JCT  Vol.3 No.6 A , November 2012
Phase I/II Study of Gefitinib and Concomitant Preoperative Radiotherapy in Patients with Locally Advanced Rectal Cancer
ABSTRACT
Objective: To determine the recommended dose (RD) of gefitinib when combined with concomitant radiotherapy (RT) in a preoperative setting in patients with locally advanced rectal cancer. Secondary objectives were to evaluate acute toxicities, pathological response rate, progression-free and overall survival (OS). Materials and Methods: 20 patients with cT3-4 or cN+ cM0 tumors were enrolled. The planned RT consisted in 50 Gy given in 2 daily fractions of 1.25 Gy in 4 weeks. During RT, gefitinib was planned to be given orally once daily with 2 successive dose levels: 250 mg and 500 mg. Rectal surgery was scheduled 5 - 6 weeks after completion of RT. The median follow-up for all patients was 57 months. Results: Among the first cohort of 6 patients, 1 patient presented a dose limiting toxicity (DLT) (Grade 3 diarrhea/dehydration). In the second cohort, 2/6 patients presented with the same DLT so that 250 mg was considered as the RD. Main acute toxicities consisted in diarrhea (grade 2 - 3, 63%), and skin reaction (in RT fields grade 2 - 3 in 42%). The 5-year actuarial OS and loco-regional control rates were of 80% and 84% respectively. Conclusion: The concomitant daily administration of 250 mg of gefitinib with 50 Gy preoperative RT is feasible with manageable toxicity. The major pathologic response rate is encouraging, though it needs further confirmation. Distant metastasis still represents a concern and new strategies to overcome this issue are warranted.

Cite this paper
A. Allal, A. Roth, A. Franzetti-Pellanda, M. Bonet, P. Gervaz and S. Bieri, "Phase I/II Study of Gefitinib and Concomitant Preoperative Radiotherapy in Patients with Locally Advanced Rectal Cancer," Journal of Cancer Therapy, Vol. 3 No. 6, 2012, pp. 970-976. doi: 10.4236/jct.2012.326124.
References
[1]   R. Sauer, H. Becker, W. Hohenberger, C. Rodel, C. Wittekind, R. Fietkau, et al., German Rectal Cancer Study Group, “Preoperative versus Postoperative Chemoradiotherapy for Rectal Cancer,” The New England Journal of Medicine, Vol. 351, No.17, 2004, pp. 1731-1740. doi:10.1056/NEJMoa040694

[2]   Swedish Rectal Cancer Trial, “Improved Survival with Preoperative Radiotherapy in Resectable Rectal Cancer,” The New England Journal of Medicine, Vol. 336, No. 14, 1997, pp. 980-987. doi:10.1056/NEJM199704033361402

[3]   C. Camma, M. Giunta, F. Fiorica, L. Pagliaro, A. Craxi and M. Cottone, “Preoperative Radiotherapy for Resectable Rectal Cancer: A Meta-Analysis,” The Journal of American Medical Association, Vol. 284, No. 8, 2000, pp. 1008-1015. doi:10.1001/jama.284.8.1008

[4]   E. Kapiteijn, C. A. Marijnen, I. D. Nagtegaal, H. Putter, W. H Steup, T. Wiggers, et al., Dutch Colorectal Cancer Group, “Preoperative Radiotherapy Combined with Total Mesorectal Excision for Resectable Rectal Cancer,” The New England Journal of Medicine, Vol. 345, No. 9, 2001, pp. 638-646. doi:10.1056/NEJMoa010580

[5]   B. G. Czito, C. G. Willett, J. C. Bendell, M. A. Morse, D. S. Tyler, N. H. Fernando, et al., “Increased Toxicity with Gefitinib, Capecitabine, and Radiation Therapy in Pancreatic and Rectal Cancer: Phase I Trial Results,” Journal of Clinical Oncology, Vol. 24, No. 4, 2006, pp. 656-662. doi:10.1200/JCO.2005.04.1749

[6]   V. Valentini, A. De Paoli, M. A. Gambacorta, G. Mantini, C. Ratto, F. M. Vecchio, et al., “Infusional 5-Fluorouracil and ZD1839 (Gefitinib-Iressa) in Combination with Preoperative Radiotherapy in Patients with Locally Advanced Rectal Cancer: A Phase I and II Trial (1839IL/0092),” International Journal of Radiation Oncology Biology Physics, Vol. 72, No. 3, 2008, pp. 644-649. doi:10.1016/j.ijrobp.2008.01.046

[7]   A. S. Allal, S. Bieri, M. Bründler, C. Soravia, P. Gertsch, J. Bernier, et al., “Preoperative Hyperfractionated Radiotherapy for Locally Advanced Rectal Cancers: A Phase I-II Trial,” International Journal of Radiation Oncology Biology Physics, Vol. 54, No. 4, 2002, pp. 1076-1081. doi:10.1016/S0360-3016(02)03003-1

[8]   M. Baumann, M. Krause, E. Dikomey, K. Dittmann, W. D?rr, U. Kasten-Pisula, et al., “EGFR-Targeted Anti-Cancer Drugs in Radiotherapy: Preclinical Evaluation of Mechanisms,” Radiotherapy Oncology, Vol. 83,No.3, 2007, pp. 238-248. doi:10.1016/j.radonc.2007.04.006

[9]   J. A. Bonner, P. M. Harari, J. Giralt, N, Azarnia, D. M. Shin, R. B. Cohen, et al., “Radiotherapy Plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck,” The New England Journal of Medicine, Vol. 354, No. 6, 2006, pp. 567-578. doi:10.1056/NEJMoa053422

[10]   K. J. Williams, B. A. Telfer, I. J. Stratford and S. R. Wedge, “ZD1839 (‘Iressa’), A Specific Oral Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor, Potentiates Radiotherapy in a Human Colorectal Cancer Xenograft Mode,” British Journal of Cancer, Vol. 86, No. 7, 2002, pp. 1157-1161. doi:10.1038/sj.bjc.6600182

[11]   A. Trotti, R. Byhardt, J. Stetz, C. Gwede, B. Corn, K. Fu K, et al., “Common Toxicity Criteria: Version 2.0. An Improved Reference for Grading the Acute Effects of cAncer Treatment: Impact on Radiotherapy,” International Journal of Radiation Oncology Biology Physics, Vol. 47, No. 1, 2000, pp. 13-47. doi:10.1016/S0360-3016(99)00559-3

[12]   B. G. Czito, J. C. Bendell, C. G. Willett, M. A. Morse, G. C. Blobe, D. S. Tyler, J. Thoma, et al., “Bevacizumab, Oxaliplatin, and Capecitabine with Radiation Therapy in Rectal Cancer: Phase I Trial Results,” International Journal of Radiation Oncology Biology Physics, Vol. 68, No. 2, 2007, pp. 472-478. doi:10.1016/j.ijrobp.2007.02.001

[13]   R. D. Hofheinz, K. Horisberger, C. Woernle, F. Wenz, U. Kraus-Tiefenbacher, G. K?hler, et al., “Phase I Trial of Cetuximab in Combination with Capecitabine, Weekly Irinotecan, and Radiotherapy as Neoadjuvant Therapy for Rectal Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 66, No. 5, 2006, pp. 1384-1890. doi:10.1016/j.ijrobp.2006.07.005

[14]   C. Rodel, D. Arnold, M. Hipp, T. Liersch, K. Dellas, I. Iesalnieks, et al., “Phase I-II Trial of Cetuximab, Capecitabine, Oxaliplatin, and Radiotherapy as Preoperative Treatment in Rectal Cancer,” International Journal of Radiation Oncology Biology Physics, Vol. 70, No. 4, 2008, pp. 1081-1086. doi:10.1016/j.ijrobp.2007.07.2356

[15]   M. Maas, P. J. Nelemans, V. Valentini, P. Das, C. Rodel, L. J. Kuo LJ, et al., “Long-Term Outcome inPatients with a Pathological Complete Response afterChemoradiation for Rectal Cancer: A Pooled Analysisof Individual Patient Data,” Lancet Oncology, Vol. 11, No. 9. 2010, pp. 835-844. doi:10.1016/S1470-2045(10)70172-8

[16]   C. Capirci, V. Valentini, L. Cionini, A. De Paoli, C. Rodel, R. Glynne-Jones, et al., “Prognostic Value of Pathologic Complete Response after Neoadjuvant Therapy in Locally Advanced Rectal Cancer: Long-Term Analysis of 566 ypCR Patients,” International Journal of Radiation Oncology Biology Physics, Vol. 72, No. 1, 2008, pp. 99-107. doi:10.1016/j.ijrobp.2007.12.019

[17]   C. Rodel, T. Liersch, R. M. Hermann, D. Arnold, T. Reese, M. Hipp, et al., “Multicenter Phase II Trial of Chemoradiation with Oxaliplatin for Rectal Cancer,” Journal of Clinical Oncology, Vol. 25, No. 1, 2007, pp. 110-117. doi:10.1200/JCO.2006.08.3675

[18]   A. Rullier, C. Laurent, M. Capdepont, V. Vendrely, P. Bioulac-Sage and E. Rullier, “Impact of Tumor Response on Survival after Radiochemotherapy in Locally Advanced Rectal Carcinoma,” American Journal of Surgical Pathology, Vol. 34, No. 4, 2010, pp. 562-568. doi:10.1097/PAS.0b013e3181d438b0

[19]   A. S. Allal and C. Soravia, “Preoperative Radiotherapy for Rectal Cancer: Beyond Local Control,” National Clinical Oncology, Vol. 3, No. 3, 2006, pp. 124-125. http://www.nature.com/nrclinonc/journal/v3/n3/full/ncponc0446.html

[20]   D. I. Rosenthal, P. J. Catalano, D. G. Haller, J. C. Landry, E. R. Sigurdson, F. R. Spitz, et al., “Phase I Study of Preoperative Radiation Therapy with Concurrent Infusional 5-Fluorouracil and Oxaliplatin Followed by Surgery and Postoperative 5-Fluorouracil plus Leucovorin for T3/T4 Rectal Adenocarcinoma: ECOG E1297,” International Journal of Radiation Oncology Biology Physics, Vol. 72, No. 1, 2008, pp. 108-113. doi:10.1016/j.ijrobp.2008.05.054

 
 
Top